1. NIAC recommends respiratory syncytial virus (RSV) vaccination with either RSVPreF3 (Arexvy®), RSVpreF (Abrysvo®) or mRNA-1345 (mRESVIA®) for those: a. aged 75 years and older b. aged 60 to 74 years with any additional risk factors for severe RSV disease* c. aged 60 years and older living in long-term care facilities for older adults.
2. A single dose is recommended; the need for booster doses has not yet been established.
3. RSV vaccines may be given at any time of the year, but vaccination will have the most individual benefit if administered just before the RSV season. The impact of any vaccination programme will depend on uptake and thus implementation factors should also be considered in determining the optimal RSV vaccination strategy for adults.
4. RSV vaccines may be given at the same time as other vaccines, such as COVID19, influenza, zoster and pneumococcal vaccines. However, co-administration studies on RSV and influenza vaccines have shown slightly lower immune responses to certain strains of influenza compared with when these vaccines are administered separately. The clinical significance of these decreased immune responses is uncertain. The benefits of giving the RSV and influenza vaccines at the same time, where there is an opportunity to do so, may outweigh such concerns.
*Risk factors for severe RSV disease may include, but are not limited to, chronic cardiovascular disease (for example, congestive heart failure, coronary artery disease), chronic respiratory conditions (for example, chronic obstructive pulmonary disease, asthma), chronic metabolic disorders (for example, diabetes mellitus), immunocompromising conditions, chronic kidney disease, chronic liver disease, chronic neurological conditions, or obesity.
